NMD4C Launch New Multi-Disciplinary Care of Neuromuscular Diseases Education Curriculum
The NMD4C is excited to share a new training and education initiative from our education team! The Multi-Disciplinary Care of Neuromuscular Diseases lecture series is a new CPD-Accredited 24-topic webinar series designed as an advanced curriculum for neurologists, physiatrists and neuromuscular fellows to learn fundamentals of multi-disciplinary care for patients across a range of neuromuscular conditions.
Designed by physiatrist Dr. Jessica Thériault, the curriculum covers a broad range of competencies including systemic complications in NMDs to rehabilitation and psychosocial support.
By attending weekly sessions, clinicians can learn or refresh their knowledge to work more effectively with their centre’s multi-disciplinary care teams and inform their own practice in the case of neuromuscular specialists who are relied on to provide expansive multi-disciplinary care for their patients.
Access the Curriculum:
Live lectures will take place from 6-7 pm ET running from Wednesday January 15, 2025 to June 25, 2025. Neurologists, Physiatrists and neuromuscular fellows interested in attending the series are welcome to register here to receive a calendar invitation. Lecture recordings will also be uploaded to LEARNMD and available to NMD4C clinical and research members.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.